Diagnostic impact of CSF biomarkers for Alzheimer's disease in a tertiary memory clinic

被引：57

作者：

Duits, Flora H. ^{[1
,2
]}

Prins, Niels D. ^{[1
,2
]}

Lemstra, Afina W. ^{[1
,2
]}

Pijnenburg, Yolande A. L. ^{[1
,2
]}

Bouwman, Femke H. ^{[1
,2
]}

Teunissen, Charlotte E. ^{[3
,4
]}

Scheltens, Philip ^{[1
,2
]}

van der Flier, Wiesje M. ^{[1
,2
,5
]}

机构：

[1] Vrije Univ Amsterdam Med Ctr, Alzheimer Ctr, Amsterdam, Netherlands

[2] Vrije Univ Amsterdam Med Ctr, Dept Neurol, Amsterdam, Netherlands

[3] Vrije Univ Amsterdam Med Ctr, Dept Clin Chem, Neurochem Lab, Amsterdam, Netherlands

[4] Vrije Univ Amsterdam Med Ctr, Biobank, Amsterdam, Netherlands

[5] Vrije Univ Amsterdam Med Ctr, Dept Epidemiol & Biostat, Amsterdam, Netherlands

来源：

ALZHEIMERS & DEMENTIA | 2015年 / 11卷 / 05期

关键词：

Dementia; Alzheimer's disease; Clinical practice; Diagnostic impact; Assessment of cognitive disorders; Cerebrospinal fluid; Amyloid-beta(1-42); Tau; Biomarkers; PROGRESSIVE SUPRANUCLEAR PALSY; CEREBROSPINAL-FLUID BIOMARKERS; MILD COGNITIVE IMPAIRMENT; ASSOCIATION WORKGROUPS; NATIONAL INSTITUTE; RESEARCH CRITERIA; DEMENTIA; RECOMMENDATIONS; GUIDELINES; MARKERS;

D O I：

10.1016/j.jalz.2014.05.1753

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Background: We aimed to assess the impact of cerebrospinal fluid (CSF) biomarkers for Alzheimer's disease on decision making and patient management in a tertiary memory clinic. Methods: We included all patients, for 1 year, visiting the VUmc Alzheimer Center for cognitive screening. Neurologists completed questionnaires before and after CSF disclosure. We assessed the change of diagnosis, diagnostic confidence, and impact on patient management. Results: A total of 438 patients (age 63 +/- 8 years, 39% women) were included, of whom 351 (80%) underwent lumbar puncture. After the disclosure of CSF 23/351 diagnoses (7%) were changed. Diagnostic confidence increased from 84% to 89% (P < .001). There were consequences for management in 44/351 patients (13%) with CSF, and 13/87 patients (15%) because of unavailable CSF. There was no effect of age on these results. Conclusions: CSF biomarkers aid clinicians with decision making during diagnostic work-up of cognitive disorders. This study may be useful for developing guidelines for the implementation of CSF biomarkers in daily practice. (C) 2015 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

引用

页码：523 / 532

页数：10

共 28 条

[1] The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease [J].

Albert, Marilyn S. ;

DeKosky, Steven T. ;

Dickson, Dennis ;

Dubois, Bruno ;

Feldman, Howard H. ;

Fox, Nick C. ;

Gamst, Anthony ;

Holtzman, David M. ;

Jagust, William J. ;

Petersen, Ronald C. ;

Snyder, Peter J. ;

Carrillo, Maria C. ;

Thies, Bill ;

Phelps, Creighton H. .

ALZHEIMERS & DEMENTIA, 2011, 7 (03) :270-279

[2] CSF markers for incipient Alzheimer's disease [J].

Blennow, K ;

Hampel, H .

LANCET NEUROLOGY, 2003, 2 (10) :605-613

[3] Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia [J].

Boeve, BF ;

Lang, AE ;

Litvan, I .

ANNALS OF NEUROLOGY, 2003, 54 :S15-S19

[4] Research criteria for the diagnosis of Alzheimer"s disease: revising the NINCDS-ADRDA criteria [J].

Dubois, Bruno ;

Feldman, Howard H. ;

Jacova, Claudia ;

Dekosky, Steven T. ;

Barberger-Gateau, Pascale ;

Cummings, Jeffrey ;

Delocourte, Andre ;

Galasko, Douglas ;

Gauthier, Serge ;

Jicha, Gregory ;

Meguro, Kenichi ;

O'Brien, John ;

Pasquier, Florence ;

Robert, Philippe ;

Rossor, Martin ;

Solloway, Steven ;

Stern, Yaakov ;

Visser, Pieter J. ;

Scheltens, Philip .

LANCET NEUROLOGY, 2007, 6 (08) :734-746

[5] Revising the definition of Alzheimer's disease: a new lexicon [J].

Dubois, Bruno ;

Feldman, Howard H. ;

Jacova, Claudia ;

Cummings, Jeffrey L. ;

DeKosky, Steven T. ;

Barberger-Gateau, Pascale ;

Delacourte, Andre ;

Frisoni, Giovanni ;

Fox, Nick C. ;

Galasko, Douglas ;

Gauthier, Serge ;

Hampel, Harald ;

Jicha, Gregory A. ;

Meguro, Kenichi ;

O'Brien, John ;

Pasquier, Florence ;

Robert, Philippe ;

Rossor, Martin ;

Salloway, Steven ;

Sarazin, Marie ;

de Souza, Leonardo C. ;

Stern, Yaakov ;

Visser, Pieter J. ;

Scheltens, Philip .

LANCET NEUROLOGY, 2010, 9 (11) :1118-1127

[6]

Duits F. H., 2014, ALZHEIMERS DEMENT

[7] Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia [J].

Engelborghs, Sebastiaan ;

De Vreese, Karen ;

Van de Casteele, Tom ;

Vanderstichele, Hugo ;

Van Everbroeck, Art ;

Cras, Patrick ;

Martin, Jean-Jacques ;

Vanmechelen, Eugeen ;

De Deyn, Peter Paul .

NEUROBIOLOGY OF AGING, 2008, 29 (08) :1143-1159

[8] Improved discrimination of AD patients using β-amyloid(1-42) and tau levels in CSF [J].

Hulstaert, F ;

Blennow, K ;

Ivanoiu, A ;

Schoonderwaldt, HC ;

Riemenschneider, M ;

De Deyn, PP ;

Bancher, C ;

Cras, P ;

Wiltfang, J ;

Mehta, PD ;

Iqbal, K ;

Pottel, H ;

Vanmechelen, E ;

Vanderstichele, H .

NEUROLOGY, 1999, 52 (08) :1555-1562

[9]

Johnson KA, 2013, ALZHEIMERS DEMENT, V9, pE1, DOI [10.1016/j.jalz.2013.06.001, 10.1016/j.jalz.2012.10.007, 10.1016/j.jalz.2013.01.002]

[10] Discriminatory and predictive capabilities of enzyme-linked immunosorbent assay and multiplex platforms in a longitudinal Alzheimer's disease study [J].

Jongbloed, Wesley ;

Kester, Maartje I. ;

van der Flier, Wiesje M. ;

Veerhuis, Robert ;

Scheltens, Philip ;

Blankenstein, Marinus A. ;

Teunissen, Charlotte E. .

ALZHEIMERS & DEMENTIA, 2013, 9 (03) :276-283

← 1 2 3 →